EyePoint, Inc. (EYPT)
EYPTNASDAQ-GMBiotechnology: Laboratory Analytical Instruments
$0.4027
+0.0408 (+11.27%) today
At the close, Nov 10, 4:00 PM ET. After hours $0.4027 -0.35%
- Market cap
- $34.84m
- P/E
- –
- EPS, last 4 quarters
- $-3.74
- Dividend yield
- –
- Day range
- $0.3600 to $0.4000
- 52-week range
- $0.3305 to $19.11
- Average volume
- 9.22m
- Previous close
- $0.3619
Analysts
13 coveringHold2 buy, 10 hold, 1 sell
Targets a year out average $2.75, +582.9% from here
Earnings
next estimate $-0.8800Next report Nov 12, 2026
Sep 2025
-10.4%
Dec 2025
-3.9%
Mar 2026
-25.3%
Jun 2026
-18.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $965.0k | $620.0k | $696.0k | $507.0k |
| Gross profit | $244.0k | $245.0k | $168.0k | $502.0k |
| Operating income | -$62.02m | -$70.34m | -$87.23m | -$97.38m |
| Net income | -$59.73m | -$67.61m | -$84.83m | -$94.47m |
Last four quarters: revenue $2.79m, margin -10998.7%, free cash flow -$271.28m
News
8 latest- Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks · Nov 2, 2026
- EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?Zacks · Oct 28, 2026
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win RTTNews · Oct 23, 2026
- Notable Monday Option Activity: EYPT, ABM, ORCLBNK Invest · Oct 19, 2026
- EyePoint's DURAVYU Misses Primary Goal Despite Reduced Treatment Burden; Stock Down RTTNews · Oct 19, 2026
- EyePoint's DURAVYU Misses Primary Endpoint In Phase 3 Wet AMD Trial RTTNews · Oct 19, 2026
- Here's Why You Should Add EYPT Stock to Your Portfolio NowZacks · Oct 15, 2026
- Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks RTTNews · Aug 21, 2026
The company
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's lead product candidate, DURAVYU, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint's proprietary bioerodible Durasert E sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME). The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- eyepoint.bio
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.